Global Immune Thrombocytopenia (ITP) Market Research Report Forecast to 2023

Published - Apr 2019 | Category - Pharma & Healthcare | No. of Pages - 105 | Published By - Market Research Future


The Global Immune Thrombocytopenia (ITP) Market is projected to grow at blooming CAGR of around 5.78% over the forecast period and market size will reach worth around 2361.2 Million US$ in 2018-2023

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by improper clotting of blood. ITP can cause excessive bruising and bleeding owing to the unusually low levels of platelets or thrombocytes in the blood. ITP can occur in both children and adults. ITP can be classified as primary, i.e., occurring on its own, or secondary, occurring alongside another condition. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP. The increasing prevalence of ITP is expected to contribute to the growth of the market over the forecast period.

Global Immune Thrombocytopenia (ITP) Market Major Key Players

Amgen Inc.
CSL Limited
Dova Pharmaceuticals
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin Co., Ltd
Ligand Pharmaceuticals, Inc
Novartis AG
Rigel Pharmaceuticals, Inc
Shire
Shionogi Inc
Others


 

Quick Buy

Latest Publications